Novel clinical assay to rapidly monitor posaconazole levels in plasma

Ended Project Grant Awarded

Award ID
R43AI155250
Recipient
Awarding agency
Obligated
$0

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Place of performance
Morrisville, NC, USA

Award details come from USAspending.gov.

Description

Abstract
Invasive fungal infections (IFIS) contribute to more than 1.5 million deaths worldwide each year and pose a serious and continuous health risk to immunocompromised individuals. The rate of mortality associated with IFI is high, and there are only four major classes of antifungal drugs available to treat IFI, of which the triazoles find greatest use. Posaconazole (PCZ; noxafil®) is the newest triazole and is the broadest spectrum, demonstrating activity against aspergillus, candida and cryptococcus species. PCZ is indicated in the U.S. For prophylaxis of invasive aspergillus and candida infections in patients at high risk for these infections, including hematopoietic stem cell transplant recipients, those with hematologic malignancies, and other immunocompromised patients. IT is also indicated for treatment of oropharyngeal candidiasis (OTC), a condition common among HIV patients. While PCZ is not associated with significant toxicities, IT displays high inter- and intra-individual variation in plasma drug concentrations, with subtherapeutic levels associated with poor efficacy. There is significant evidence to demonstrate that inadequate exposure to antifungals is independently associated with increased hospital mortality, and the infectious diseases society of america recommends therapeutic drug monitoring (TDM) of PCZ to ensure adequate treatment. Unfortunately, there are currently no FDA approved assays available for performing PCZ TDM. Available assays remain limited to institutions or laboratories that have developed in-house laboratory-developed tests that rely on high- performance liquid chromatography (HPLC) or HPLC with mass spectrometry. These complex assays are expensive and lack harmonization, making IT impossible to compare results from one test to the next. Most importantly, the turnaround time can range from several days to a week, making routine dose adjustments based on timely results impossible. Affinergy plans to develop a novel locking assay for the direct measurement of PCZ levels in plasma that is compatible with common clinical chemistry analyzers to facilitate routine TDM. Our assay with its lower cost and rapid turnaround will open access to a majority of patients to ensure that therapeutic levels are achieved to prevent life-threatening breakthrough infections and help control the rise of resistant strains.

Quick answers

Who received award R43AI155250?

R43AI155250 was awarded to Affinergy, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 23, 2024.

How much is award R43AI155250 worth?

$0 has been obligated on R43AI155250.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award